BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q1 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $721,000 | -1.2% | 8,523 | -6.0% | 0.19% | -5.9% |
| Q4 2020 | $730,000 | -15.0% | 9,063 | -14.9% | 0.20% | -23.0% |
| Q3 2020 | $859,000 | -7.4% | 10,654 | -0.9% | 0.26% | -14.5% |
| Q2 2020 | $928,000 | +6.1% | 10,751 | +0.0% | 0.31% | -14.4% |
| Q1 2020 | $875,000 | -2.9% | 10,750 | 0.0% | 0.36% | +16.8% |
| Q4 2019 | $901,000 | -6.3% | 10,750 | -2.0% | 0.31% | -12.9% |
| Q3 2019 | $962,000 | +0.4% | 10,966 | -6.0% | 0.36% | -0.3% |
| Q2 2019 | $958,000 | +0.7% | 11,669 | +0.0% | 0.36% | +0.8% |
| Q1 2019 | $951,000 | +22.4% | 11,668 | -1.2% | 0.35% | +9.9% |
| Q4 2018 | $777,000 | -22.8% | 11,812 | -9.7% | 0.32% | -9.8% |
| Q3 2018 | $1,007,000 | +4.0% | 13,074 | 0.0% | 0.36% | -3.5% |
| Q2 2018 | $968,000 | +17.8% | 13,074 | +0.8% | 0.37% | +11.1% |
| Q1 2018 | $822,000 | -5.3% | 12,973 | -3.2% | 0.33% | -7.2% |
| Q4 2017 | $868,000 | -8.7% | 13,397 | -11.4% | 0.36% | -12.9% |
| Q3 2017 | $951,000 | -3.5% | 15,117 | -6.9% | 0.41% | -5.7% |
| Q2 2017 | $985,000 | +6.5% | 16,241 | -2.2% | 0.44% | +6.8% |
| Q1 2017 | $925,000 | +8.1% | 16,611 | -5.0% | 0.41% | +8.5% |
| Q4 2016 | $856,000 | -10.5% | 17,486 | -13.0% | 0.38% | -50.1% |
| Q3 2016 | $956,000 | – | 20,088 | – | 0.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |